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Ethnopharmacological relevance: Operculina macrocarpa is an ornamental climbing plant of the North-
eastern Brazil extensively used in traditional medicine as depurative of the blood and for the treatment
of thrombosis. To investigate the antiplatelet and anticoagulant potential of Operculina macrocarpa and to
determine the possible mechanisms of action.
Material and methods: The Operculina macrocarpa tincture (OMT) was characterized by the polyphenol
content and chromatographic proﬁle established by HPLC with detection and quantiﬁcation of three
phenol acids (caffeic, clorogenic and gallic acids). The human platelet aggregation was induced in vitro by
the agonists ADP, collagen, thrombin, epinephrine or arachidonic acid, and the antiplatelet effect of OMT
was evaluated in the presence or absence of aspirin (a nonselective inhibitor of cyclooxygenase),
pentoxifylline (a phosphodiesterase inhibitor), ticlopidine (a P2Y12 purinoceptor antagonist) or ODQ
(a selective inhibitor of guanilate cyclase). The effect of OMT on the partial thromboplastin time,
prothrombin time and bleeding time were investigated on human or rat plasma.
Results: The strongest antiplatelet effect of OMT (50–400 mg/mL) was observed on the ADP- induced
aggregation with inhibitions up to 55%, while among others agonists (epinephrine, collagen, thrombin
and arachidonic acid) maximal inhibitions reached by OMT (200 mg/mL) were on platelet aggregation
induced by collagen (18%) or epinephrine (20%). The antiplatelet effect of OMT (400 mg/mL) was
comparable to aspirin, a nonspeciﬁc inhibitor of cyclooxygenase. The ticlopidine and pentoxifylline
increased 5.1 and 3.8 fold the inhibitory effect of OMT on ADP-induced platelet aggregation, respectively.
On the other hand, L-arginine, ODQ and aspirin showed a slightly or no effect on antiplatelet effect of
OMT. The bleeding time in rats was signiﬁcantly increased by OMT, but the tincture did not interfere on
the activated partial thromboplastin or prothrombin time in human plasma.
Conclusions: This study showed that the tincture of Operculina macrocarpa has antiplatelet effect that
cannot be attributed to a single biochemical mechanism and at least part of it cannot be related to the
OMT inhibition of P2Y12 purinergic receptors.
& 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The participation of platelets in hemostasis is of fundamental
importance to the normal physiology. Circulating platelets in normal
conditions must be able to maintain a direct and repeated contact
with the vessel wall without premature activation. On the other hand,
after a vascular injury, the platelets must recognize the damaged wall,
adhere and form a stable clot, which will remain in place until repair is
no more needed (Brass, 2010). When there is an injury to the blood
vessel wall or endothelial cell layer, platelets adhere to the site of
injury by binding to von Willebrand factor (vWF) and collagen ﬁbrils
in the sub-endothelial matrix. Subsequently, platelet are stimulated to
secrete various molecules such as adenosine diphosphate (ADP) and
thromboxane A2 (TXA2), which activate neighboring platelets, and
increase the expression of membrane integrins including glycoprotein
IIb/IIIa (GP IIb/IIIa) receptors, which form bridges between adjacent
platelets by binding to ﬁbrinogen. These processes lead to the
formation of a platelet plug at the injury site (Davi and Patrono, 2007).
Thrombosis refers to a pathological formation of a hemostatic
plug within the blood vessels in the absence of bleeding. Arterial
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thrombosis is an acute complication that develops in association
with atherosclerosis and causes cardiovascular diseases such as
ischemic heart disease and stroke (Ruggeri, 2002; Davi and
Patrono, 2007). Platelets are critical components in thrombosis
and may participate in the progression of the atherosclerotic
plaque (Ruggeri, 2002; Jennings, 2009). Thrombotic diseases,
especially heart disease and cerebral vascular thrombosis became
the leading causes of death and its incidence is increasing every
year (Bao et al., 2009).
Antiplatelet agents such as aspirin and clopidogrel are widely
used clinically and directly inhibit platelet aggregation (Gaglia et al.,
2010). However, the continuous use of these agents is limited
because they can induce resistance or adverse effects such as head-
ache, abdominal cramps, vomiting and gastric ulceration (Angiolillo
et al., 2007). For these reasons, a number of studies (Tsai et al., 2000;
Ballabeni et al., 2007; Ryu et al., 2009) have been conducted to search
new medicines from synthetic or natural source.
Several authors have shown the antiplatelet effect of extracts or
molecules from medicinal plants and their constituents, such as
Amburana cearensis (Leal, 1995) and piplartine, an alkamide iso-
lated from Piper tuberculatum (Fontenele et al., 2009).
Operculina macrocarpa (L.) Urb (Convolvulaceae), is an ornamental
climbing plant of the Northeastern Brazil popularly known as
“jalapa” or “batata-de-purga”. The roots of this plant are mainly used
in traditional medicine as depurative of the blood (Matos, 1982). In
addition, a phytomedicine entitled “Aguardente Alemã” an ethanolic
solution (tincture) produced from Operculina macrocarpa (OMT)
associated with Convolvulus scamnonia is extensively used in folk
medicine in the Northeastern Brazil for the treatment of circulatory
diseases such as thrombosis (Carvalho et al., 2003). In this sense, the
objective of this present study was to investigate the antiplatelet and
anticoagulant effects of Operculina macrocarpa.
2. Materials and methods
2.1. Drugs, chemicals and phytomedicine
Adenosine diphosphate (ADP), dimethylsulfoxide (DMSO), Tween
80, acetylsalicylic acid (ASA), 1H-[1,2,4] oxadiazolol [4,3-a] quinoxalin-
1-one (ODQ), L-arginine, caffeic acid, chlorogenic acid and gallic acid
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Arachidonic
acid and thrombinwere purchased from Chrono-log (USA). Pentoxifyl-
line (Trentals) and ticlopidine (Ticlids) were obtained from Sanoﬁ-
Aventis (Brazil). Sodium nitroprusside (Nitrops) was obtained from
Hypofarma (Brazil). Heparin (Liquemines) was obtained from Roche
(Brazil). Collagen and epinephrine were purchased from Helena
Laboratories (USA). Triﬂuoroacetic acid was obtained from VETEC
(Brazil), while acetonitrile was originally provided by TEDIA (Brazil).
All others reagents were of analytical grade.
2.2. Samples of human blood
Blood samples were obtained from healthy volunteers who had
not taken any drugs for at least ﬁfteen days. The study was
approved by the Human Research Ethics Committee of the Federal
University of Ceará, Brazil, under the number 169/10.
2.3. Animals
Male Swiss mice (25–30 g) were housed in standard environ-
mental conditions (2371 1C, humidity 6075% and a 12 h/12 h
dark/light cycle-light on at 7.00 a.m.), with food and water
available ad libitum in accordance to the Guide for the Care and
Use of Laboratory Animals, US Department of Health and Human
Services, 1985. All experiments were conducted in a quiet room at
a constant temperature of 25 1C. All drugs were administered
orally at a volume of 10 mL/kg. The experiments were approved by
the Animal Research Ethics Committee, Federal University of Ceará
(registered under No. 63/10).
2.4. Operculina macrocarpa tincture
The tincture from the roots of Operculina macrocarpa (resin
content: 1.3870.47 g% w/v) was obtained from the Ravick Che-
mical Products and Cosmetics Laboratory (Fortaleza, CE, Brazil).
The plant was collected in the city of Parnaíba (Piauí, Brazil)
located at coordinates 21 54′49″ S and 411 47′15″ W. The botanical
material was identiﬁed by the Herbarium Prisco Bezerra, Federal
University of Ceará (voucher specimen registered under the
number 45489).
2.5. Chemical characterization of Operculina macrocarpa
The chromatographic analysis by high-performance liquid chro-
matography (HPLC) of OMT was performed according the method
described by Michelin (2008). The assays were performed on Alliance
—Waters 2695 (Milford, MA) chromatograph with a binary pump,
auto-sampler, and photodiode-array detector (Waters-2996 PDA) at
310 nm. The separations were performed with an analytical reverse-
phase column C18 (Varians, 2504.65 mm) and a guard column
(Phenomenexs, 435 mm) at 40 1C in a thermostatic oven. The
mobile phase was made from water/triﬂuoroacetic acid (mobile
phase A) and acetonitrile/triﬂuoroacetic acid (mobile phase B) in a
gradient mode for 31 min (total run time) by varying the mobile
phase B from 10 to 100% at 1.0 mL/min ﬂow rate. The solvents were
previously degassed under vacuum by sonication during 5 min and
ﬁltered through Phenomenex nylon membrane (0.45 μm). The
samples were dissolved in the initial mobile phase and ﬁltered
through Waters PTFE membrane (0.45 μm) before injection (20 mL).
The data was processed by Empowers (Waters, USA) software.
The identiﬁcation of caffeic, chlorogenic and gallic acid in
Operculina macrocarpa tincture by HPLC experiments were based
on the retention time (rt) of external standards. The contents of
the three phenol acids in the tincture were calculated using
calibration curves. The ranges of calibration curves were 0.01–
0.015 mg/mL for chlorogenic acid and gallic acid, 0.001–0.005 mg/
mL for caffeic acid. The linear relationship was obtained correlat-
ing the concentration of phenols acids to the correspondent peak
area. The linear regression equations were determined and the
correlation coefﬁcients for and caffeic acid, chlorogenic acid and
gallic acid were 0.996, 0.998 and 0.993, respectively. The content
of phenols acids were expressed as mean of three determinations
and coefﬁcient of variation.
2.6. Measurement of total polyphenol content and phytochemical
prospecting in OMT
The determination of the total polyphenol contents of OMT was
measured by the Folin–Ciocalteu colorimetric method (Singleton
and Rossi, 1965). An aliquot (100 μL) of the OMT was mixed to
250 μL of Folin–Ciocalteu reagent (1 N). The mixture was shaken
before adding 1250 μL Na2CO3 (20%) and adjusting with Milli-Q
water to a ﬁnal volume of 10 mL. After 40 min of standing in dark,
the mixture was analyzed by spectrophotometry (Beckman Coulter
DU 640, Germany) at 715 nm. The amount of total polyphenols was
calculated through calibration curve (linear regression equation:
y¼0.077xþ0.0468; r¼0.9985) of gallic acid (4–16 μg/mL). Results
were expressed as gram gallic acid equivalents (GAE) per mL of OMT.
The phytochemical proﬁle of the OMT was performed accord-
ing to the method described by Matos (2009) and identiﬁcation
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reactions based on the chemical group to be determined or by thin
layer chromatography.
2.7. Platelet aggregation test
2.7.1. Preparation of platelet-rich and platelet-poor plasma
Blood from healthy volunteers was collected by venipuncture
into silicon coated glass ﬂasks containing 3.8% sodium citrate
(9:1 v/v). Platelet-rich plasma was prepared by centrifugation of
blood at 1000 rpm for 10 min at room temperature. Platelet-poor
plasma was obtained immediately afterwards by centrifugation of
an aliquot of platelet-rich plasma at 1500 rpm for 10 min. The
platelets were counted according to the method of Brecher and
Cronkite (1950) and adjusted to a concentration of 300,000/mm3.
2.7.2. Aggregation in platelet-rich plasma
Platelet aggregation was measured with an aggregometer (model
450, Chrono-Log Co., USA) according to the method of Born and Cross
(1963). Brieﬂy, after stirring at 1200 rpm, platelet aggregation was
induced at 37 1C, by addition of ADP (2 mM), AA (1 mM), thrombin
(1 U/mL), collagen (2 mg/mL) or epinephrine (EPI 40 mM) as agonists.
Operculina macrocarpa tincture—OMT (50–400 mg/mL) or 0.08% DMSO
in water (vehicle, control) were added 10min before the addition of
the agonist. The resulting aggregation, measured as the change in light
transmission, was recorded for 8 min. Values are presented as
percentage aggregation compared with the control (100%).
Evaluation of the OMT antiplatelet effect in presence of other
antiplatelet agents in human plasma in vitro.
The effect of the OMT (100 mg/mL) was evaluated in the
presence of drugs as acetylsalicylic acid (ASA 25 mM), ticlopidine
(TIC 250 mM) or pentoxifylline (PTX 120 mg/mL), and aggregation
was induced by ADP (2 μM). The OMT and/or antiplatelet agents
were incubated in PRP before the agonist.
2.7.3. OMT antiplatelet effect in human plasma and
the role of nitric oxide/guanylate cyclase
The antiplatelet effect of OMT (100 mg/mL) was investigated in
the absence and in the presence of L-arginine (L-ARG 10 mg/mL) or
ODQ (2 mM). The ADP (2 mM) was used as an agonist of platelet
aggregation and sodium nitroprusside (SNP 10 μM), a nitric oxide
donor, as standard drug (Jang et al., 2002).
2.8. Anticoagulant tests
2.8.1. Determination of the bleeding time in mice
The bleeding time was determined using a method described by
Huang et al. (2007). Male Swiss mice were divided in groups of ten
and pre-treated with OMT (100, 200, 400 mg/kg), with the tincture
vehicle (Tween 80 4% in water, control), with water (normal) or ASA
(100 mg/kg) (a standard, COX nonspeciﬁc inhibitor), p.o., once a day,
for ten days. One hour after the last administration, the mouse tail
was transected about 1 cm from the tip using a disposable surgical
blade. The bleeding time was measured from the time of transection
until it was completely stopped. The blood was absorbed with ﬁlter
paper at 20 s intervals during bleeding.
2.8.2. In vitro anticoagulation activity
Anticoagulation activity was evaluated by measuring the plasma
clotting times (aPTT and PT) by a modiﬁcation of the method of Yuk
et al. (2000) using a coagulometer (Teco, Coatron M1, Germany) and
commercial kits Hemostat thromboplastin SI and Hemostat aPTT
(Human, Alemanha). Platelet-poor plasma was incubated with OMT
(200 and 400 mg/mL), DMSO (0.08%) (vehicle, control) or heparin (0.1
ou 0.5 UI/mL, standard, anticoagulant) for 10 min at 37 1C.
To evaluate the activated partial thromboplastin time (aPTT), in the
human plasma (50 μL) previously incubated with OMT was added
cephalin (50 μL) and clotting was started by adding CaCl2 (50 mL). For
evaluating the prothrombin time (PT), the human plasma (50 μL)
preincubated with OMT, was mixed with calcium thromboplastin
(100 μL) and then measured the time of clot formation.
2.9. Statistical analysis
The statistical analysis was performed using the GraphPad
Prism version 5.0 (USA). The results were expressed as mean7-
standard error of mean (SEM). For multiple comparisons the
Analysis of Variance (ANOVA) followed by Tukey as the post hoc
test were used. Probability levels of less than 5% were considered
statistical signiﬁcant (npo0.05).
3. Results
3.1. Chemical characterization of Operculina macrocarpa
tincture (OMT)
The HPLC analysis permitted to detect, identify and quantify three
phenol acids in OMT, such as caffeic acid—CA (rt¼9.1 min), gallic acid
—GA (rt¼3.0 min) and chlorogenic acid—CLA (rt¼7.4 min) (Fig. 1).
The content of CA, GA and CLA in OMT were of 0.03 (7.5), 0.14 (1.6)
and 0.17 (4.4) mg/mL, respectively. The polyphenol content of OMT
was 0.14 g GAE/mL of OMT. In addition, chemical studies carried out
with the OMT demonstrated the presence of tannins, phenols and
coumarins.
Fig. 1. Chromatogram generated by the HPLC-PDA system for Operculina macrocarpa tincture. Gallic acid (1); chlorogenic acid (2) and caffeic acid (3). Conditions: C18 column
(2504.6 mm, 5 mM) mobile phase (A: water/TFA B: AcN /TFA) gradient elution, ﬂow 1.0 mL/min and wavelength 310 nm.
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Effects of OMT on platelet aggregation induced by ADP, throm-
bin, arachidonic acid, collagen or epinephrine in human plasma.
The addition of OMT (50, 100, 200, 300 and 400 mg/mL) on
human platelet suspension reduced signiﬁcantly the platelet
aggregation induced by ADP with inhibitions of up to 55% (IC50
value: 363.07 mg/mL). Fig. 2 shows the original record of this effect
of OMT (100, 200 and 400 mg/mL) on ADP-induced platelet
aggregation in human plasma.
The OMT was investigated for its effect on human platelet
aggregation induced by other agonists such as epinephrine, collagen,
arachidonic acid and thrombin. The OMT (200 μg/mL) inhibited
signiﬁcantly the platelet aggregation induced by epinephrine (20%)
or collagen (18%) but no signiﬁcant effect on thrombin or arachidonic
acid-induced platelet aggregation was observed (data not shown).
3.1.1. Evaluation of the antiplatelet effect of the OMT in the absence
and presence of aspirin, pentoxifylline or ticlopidine in human plasma
The addition of OMT (100 mg/mL) in the presence of ASA
(25 μM), on platelet suspension did not induce any signiﬁcant
change in the antiplatelet effect of OMT (aggregation: 64.576.4%)
when compared to OMT alone (aggregation: 77.472.8%) on ADP-
induced platelet aggregation. The evaluation of the antiplatelet
effect of OMT (100 μg/mL) in the presence of pentoxifylline (PTX,
120 mg/mL) or ticlopidine (TIC, 250 mM) showed a signiﬁcant
decrease in the percentage of aggregation (OMTþPTX: 72.074.4;
OMTþTIC: 18.772.8) as compared to OMT alone, where the
percentage of aggregation was around 92 (Fig. 3).
3.1.2. OMT antiplatelet effect in human plasma: Role of NO/GC/cGMP
In order to verify whether the NO/GC/cGMP system has a role in
the antiplatelet effect of OMT, L-arginine (10 mg/mL) a substrate for
nitric-oxide synthase, was preincubated with OMT (100 μg/mL) prior
to the percentage of ADP-induced platelet aggregation. The effect of
OMT (91.271.9%) was signiﬁcantly modiﬁed by L-arginine (OMTþ
L-ARG: 81.673.0%), although it induced an increase of only 9.6% of
the antiplatelet effect of OMT (Fig. 3). The combination of OMT with
ODQ, an inhibitor of guanylate cyclase, did not reverse the antiplate-
let effect of OMT (OMT and ODQþOMT: 84.172.9% and 73.375.9%,
respectively). Different results were observed for sodium nitroprus-
side (SNP: 37.875.2%), a NO donor, which had its antiplatelet effect
signiﬁcantly reversed by preincubation with ODQ (ODQþSNP:
103.674.0%) (data not shown).
3.1.3. Effect of OMT on the bleeding time in mice
The pretreatment of mice with OMT (400 mg/kg, p.o.)
increased signiﬁcantly the animals bleeding time (10.371.0 min)
when related to the control group (3.370.3 min). Similar results
were observed in animals pretreated with ASA at concentration of
100 mg/kg, p.o. (13.271.9 min) (Fig. 4).
3.1.4. Effects of the OMT in the activated partial thromboplastin
time (aPTT) and prothrombin time (PT) in human plasma
The OMT (200 and 400 mg/mL) did not increase the aPTT
(46.671.6 and 51.573.8 s, respectively) when related to the control
group (40.371.2 s), while heparin (0.1 U/mL), an anticoagulant drug,
increased signiﬁcantly the aPTT (100.977.6 s). The addition of OMT
(200 and 400 mg/mL) to human plasma did not increase the TP
(12.570.2 and 13.970.4 s) as compared to the control group
(11.770.2 s).
4. Discussion
The present study showed for the ﬁrst time the effect of
Operculina macrocarpa tincture (OMT) on human platelet aggrega-
tion, as well as performed a preliminary evaluation of its antic-
oagulant potential.
The OMT was chemically characterized by spectrophotometric and
HPLC analysis which determined the polyphenol and phenols acids
content such as caffeic acid, gallic acid and chlorogenic acid. In
addition, coumarins and tannins where also identify in the OMT. In
this context, the polyphenols content of OMT determined in the
present study was possibly related at least in part with the presence of
phenol acids, coumarin and tannins in plant. These data corroborate a
previous study (Michelin, 2008), which showed the presence of
various phenolic compounds in the ethanolic extract of Operculina
macrocarpa, such as chlorogenic acid, caffeic acid, caffeic acid dimer
and protocatechuic acid, besides coumarins, triterpenes and reducing
sugars.
The OMT inhibited the ADP-induced platelet aggregation, a
primary agonist that induces platelet aggregation by a mechanism
independent of the production or release of others mediators by
platelets. The activation of platelets by ADP involves at least three
receptor types. The P2Y1 purinergic receptor, which is coupled to G
protein, causes the mobilization of intracellular calcium, and is
responsible for platelet shape change, while the P2Y12, Gi protein
coupled receptor, causes the inhibition of adenylate cyclase and the
ampliﬁcation of the ﬁnal response. A third receptor, the P21
mediates the ionic ﬂuxes and is more sensitive to ATP (Cattaneo
and Gachet, 2001).
Several studies (El Haouari et al., 2006; Gadi et al., 2012) have
shown the antiplatelet effect of phenolic compounds, including
ﬂavonoids and phenols acids. Evidences (Cho et al., 2012) showed
that the chlorogenic acid (10–50 mM) has antiplatelet activity in
human platelets collagen and ADP-induced aggregation. Other studies
(Hsiao et al., 2007; Cheng et al., 2007) also demonstrated that a
derivative of caffeic acid (6–25 mM) is capable of inhibiting platelet
aggregation induced by collagen, and that this inhibition appears to be
modulated by an increase in cGMP levels. Furthermore, gallic acid
(100–1000 mM) was shown to be also capable of inhibiting the platelet
aggregation induced by ADP, TXA2 analog, collagen and arachidonic
acid (Chang et al., 2012; Lim et al., 2004). Thus, it is possibly that
the chlorogenic, caffeic and gallic acids present in the tincture of
Operculina macrocarpa (480, 167 and 823 mM, respectively), may be
responsible at least in part for the antiplatelet activity of this plant.
However, the possible participation of other compounds present in
this species, such as coumarin and tannins, cannot be ruled out.
The OMT reduced signiﬁcantly the platelet aggregation induced
by ADP, collagen and epinephrine, but it showed no effect on
ADP 2µM
DMSO 0,08%
OMT 100µg/mL
OMT 200µg/mL
OMT 400µg/mL
Fig. 2. Original record of the effect of Operculina macrocarpa tincture (OMT) on
ADP-induced platelet aggregation in human plasma. PRP was incubated for 10 min
with OMT (100–400 mg/mL) or DMSO 0.08% in water (control) prior the addition of
ADP (2 mM).
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thrombin or arachidonic acid-induced platelet aggregation. After an
injury, the collagen on the subendothelial region, is on the surface of
the vascular wall and has an important role in platelet activation, an
event that starts the process of lesion repairing (Clemetson, 1999). As
the collagen may interact with several proteins, a wide variety of
receptors have been described for this agonist (Colman, 1991).
However, studies suggest that the glycoprotein Ia/IIa (GPIa/IIa) and
glycoprotein VI (GPVI) have a role in modulating platelet aggregation
induced by collagen (Ruggeri and Savage, 2007).
Epinephrine may exert its effects on platelet aggregation by various
signaling pathways, as the metabolism of AA (with formation of TXA2,
increased levels of intracellular Ca2þ , exposure of the GPIIb/IIIa, release
of ADP and others), or by hydrolysis of phosphatidylinositol
(via phospholipase C, with mobilization of cytoplasmic Ca2þ , and
previously stimulated adenylate cyclase prostaglandin GI2 or prosta-
glandin E1). However, it is important that the effects of epinephrine
appear to be mediated through activation of α2-adrenergic receptors
present in platelets (Yun-Choi et al., 2000), which are of the subtype
α2A (Mustonen et al., 2000). Taken together, the results of the present
study demonstrated that the antiplatelet effect of OMT cannot be
attributed to a single biochemical mechanism and it is possibly
inﬂuenced by several pathways involved with the platelet function.
The association of OMT with PTX, ASA or L-ARG induced a
slight increase (20, 12.9 and 9.6%, respectively) in the antiplatelet
effect of this tincture, but only PTX and L-ARG changed signiﬁ-
cantly the effects of OMT. Our data showed that the ODQ, an
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inhibitor of the soluble guanylate cyclase, did not interfere with
the antiplatelet effect of OMT. Together, these data suggest that the
COX pathway, NO and cyclic nucleotide levels may play a role in
the antiplatelet effect of OMT. However, OMT appears to modulate
the levels of cyclic nucleotides without causing a direct stimula-
tion of guanylate cyclase.
Studies have shown that the clopidogrel and ticlopidine, plate-
let antiaggregant drugs exert their effects by inhibiting the action
of ADP in the P2Y12 receptors (Ohlmann et al., 2000; Hollopeter
et al., 2001). In the present study it was observed that the
inhibitory action of OMT on platelet aggregation was increased
by 65.4% in the presence of ticlopidine. Thus, our ﬁndings suggest
that the antiplatelet effect of OMT seems not to be related the
participation of this purinergic receptor (P2Y12). In addition, some
other possible mechanism unrelated to purinergic receptor also
seem to account for the antiplatelet effect of OMT.
Like ASA, the OMT (400 mg/kg) induced a signiﬁcant increase
in the bleeding time in mice. These ﬁnding are in accordance with
other study (De Gaetano et al. 1977), which showed that the
inhibition of ADP-induced but not collagen-induced platelet
aggregation determines the prolongation of the bleeding in rats.
The OMT did not show anticoagulant effect investigated by aPTT
and PT assays in human plasma.
In conclusion, our study demonstrated an unprecedented way
that OMT has anti-platelet activity, which appears to result.
5. Conclusion
In conclusion, our study demonstrated an unprecedented way
that the tincture from Operculina macrocarpa has antiplatelet
effect, which appears to result from several intracellular actions
that seems not to be related the participation of P2Y12 receptors.
In addition, an independent purinergic receptor mechanism for
the OMT action must be account such as COX system, NO and
cyclic nucleotides levels. The OMT effect is possibly related at least
in part, to the presence of phenols compounds in this product.
Finally, the results of the present study agree with the popular use
of Operculina macrocarpa for the treatment of circulatory diseases
such as thrombosis. Additional studies to further chemical char-
acterization of the OMT and establish the precise pharmacological
mechanisms of action of OMT are in development.
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